nteraction between members of the tumor necrosis factor superfamily (TNFSF) and their receptors (eg, TNF-, CD40/CD40L and LIGHT/TR2) elicit diverse biological responses that are known to be involved in atherogenesis. [1] [2] [3] These responses include the induction of pro-inflammatory cytokines, matrix metalloproteinases (MMPs), adhesion molecules, and tissue factor, and are known to make plaque unstable. 4 TWEAK (TNFSF12) has multiple biological activities, including stimulation of cell growth, induction of inflammatory cytokines, and stimulation of apoptosis. 5 The receptor for TWEAK is known to be TweakR/Fn14. 6 The expression of TWEAK is induced in peripheral blood monocytes by interferon-gamma (IFN-). 7 Because IFN-expression has been detected in atherosclerotic plaques, 8 it is expected that TWEAK is expressed by macrophage cells in atherosclerotic plaques. Therefore, we investigated the expression of TWEAK in atherosclerosis and the possible cellular responses induced by TWEAK.
Human carotid endoarterectomy tissues were obtained from 13 patients (aged 63-81 years, who underwent surgery at the Samsung Seoul Hospital) after informed consent was given. Immunohistochemical analysis of the atherosclerotic plaques revealed TWEAK and TweakR/FN14 expressions in regions rich in foam cells (Fig 1, Top panel IFN-has been reported to be expressed in atherosclerotic plaques and to regulate the expression of the macrophage scavenger receptor. 9 IFN-was also found to be involved in atherogenesis, by acting on smooth muscle cells to potentiate growth-factor-induced mitogenesis, 10 and is known to induce the expression of TWEAK in peripheral blood monocytes. 11 Thus, the expression of TWEAK in foam cells in atherosclerotic plaques is likely to be induced by IFN-in combination with other atherogenic stimuli. TWEAK expressed by foam cells in atherosclerotic plaques will autostimulate itself through TweakR/FN-14.
Flow cytometry using anti-TweakR/FN14 monoclonal antibody revealed that the THP-1 cells (ATCC, Rockville, MD, USA) expressed a high basal level of TweakR/FN14 (Fig 2A) . To find out the cellular responses induced by TWEAK, we treated THP-1 cells with recombinant human soluble TWEAK protein (rhsTWEAK; Alexis, San Diego, CA, USA). Stimulating THP-1 cells with rhsTWEAK induced the expression of MMP-9 in a dose-dependent manner, as observed in a gelatin zymogram (Fig 2B) . Treatment of THP-1 cells with rhsTWEAK induced proatherogenic cytokines, such as IL-6, IL-8, and MCP-1. Interestingly, the treatment of THP-1 cells with 100 U/ml of IFN-in combination with 100 or 300 ng/ml of TWEAK resulted in the synergistic activation of IL-8, IL-6, and MCP-1 (Fig 2C) . For the assay, THP-1 cells (1×10 5 /well) were seeded in 100 l of serum-free RPMI1640 medium in 96-well plates. The supernatants were collected 24 or 48 h after activation and MMP-9 expression was measured by gelatin zymogram and cytokines were measured by sandwich ELISA (Endogen Inc, Woburn, MA, USA).
Activation of NF-B has been reported to play an important role in the activation of pro-inflammatory cytokines and MMPs; a recent study showed that TWEAK initiates 
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NF-B signaling pathways. 12 Therefore, we investigated whether TWEAK causes NF-B activation by electrophoretic mobility shift assay (EMSA). THP-1 cells were activated as described earlier. Nuclear extracts (10 g) were mixed with poly (dI-dC) · poly (dI-dC) (1 g) in 10-30 l of binding buffer (20 mmol/L HEPES, pH 7.9, 20% glycerol, 100 mmol/L KCl, 0.2 mmol/L EDTA, 10 mmol/L DTT, and 30 mmol/L PMSF). End labeled NF-B probe (Promega, Madison, WI, USA) (0.002-0.008 pmol/5,000 cpm) was added 5 min later, and the cells were incubated for 20 min at room temperature. Next, 1 l of dye was added to each tube, the mixture was applied to a 4% polyacrylamide gel and electrophoresed. For supershift analysis, 1 g of antip65 antibody (SantaCruz Biotechnology, San Diego, CA, USA) was added during the 20 min incubation period before electrophoresis. As shown in Fig 2D, (Fig 2E) . Western blot analysis was performed as described previously. 13 To confirm that the activation of NF-B by TWEAK is required for the induction of MMP-9, we pre-treated THP-1 cells with the NF-B inhibitor, PDTC, before TWEAK activation. PDTC inhibited the activation of MMP-9 in a dose-dependent manner, and pretreatment with 20 mol/L of PDTC blocked the activation of MMP-9 (Fig 2F) . To rule out the possibility of cytotoxic effects of PDTC, we carried out cell viability test at 24 and 48 h after treatment with 20 mol/L PDTC; we did not detect any decline of THP-1 cell viability after PDTC treatment (data not shown), which indicates that TWEAK-mediated activation of MMP-9 requires activation of NF-B.
Our results suggest that TWEAK is involved in atherogenesis via the induction of pro-atherogenic cytokines and extracellular matrix degrading enzymes. These responses are known to decrease the stability of the plaques by activating other cell types and weakening the fibrous cap that covers the atherosclerotic plaque. Because these functions have been substantively linked to other members of the TNFSF, it is reasonable to expect that TWEAK is a contributory factor in atherosclerosis. Further investigations are needed to determine whether blocking the interaction between TWEAK and TweakR/FN14 will suppress the atherogenic process.
